5Hicks LD, Hyatt JL, Stoddard S, et al. Improved, sdective, human intestinal carboxylesterase inhibitors designed to modu- late 7-ethyl-10 [- 4-( 1-piperidino ) 1-piperidino ] earbonyloxy- camptotheein (Irinoteean;CPT-11) toxieityEJ]. J Med Chem, 2009,52(12) :3742 3752.
6De Jong FA, Kehrer DF, Mathijssen RH, et al. Prophy-laxis of irinoteean-induced diarrhea with neomycin and po-tential role {or UGTIA1 ~ 28 genotype screening: a double-blind, random- ized, placebo-controlled study E J ]. Oneologist, 2006, 11 ( 8 ) : 944-954.
6Hidalgo M, Siu LL, Nenmnaitis J,et al.Phase I and phannacologic study of 0SI-774,an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignmncies[J] .J Clin Oncol,2001,19 (13) :3267.
7Brouatd M, Saurat JH. Cutaneous reactions to STI 571[J]. N Engl J Med, 2001,345(8) :618.
8Desai J, Yassa L, Margusee E, et al. Hypothyroidism after sunitinib treatment for patients with trointefinal stromal tumors[J]. Ann Intern Med,2006, 145(9) :660.
9Limonti A,Gelibter A,Pavess I, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens [J]. Cancer Treat Review, 2004,30 (6): 555.
10Yasuyuki S, Sachiyo H, Sadao H.Effect of liposomalization on the antitumor activity, side - effects and tissue distribution of CPT-11[J]. Cancer Letters, 1998, 127 (2):99.
